
DMH-25
CAS No. 1685280-21-0
DMH-25( —— )
Catalog No. M22216 CAS No. 1685280-21-0
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 178 | Get Quote |
![]() ![]() |
5MG | 268 | Get Quote |
![]() ![]() |
10MG | 408 | Get Quote |
![]() ![]() |
25MG | 672 | Get Quote |
![]() ![]() |
50MG | 945 | Get Quote |
![]() ![]() |
100MG | 1278 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameDMH-25
-
NoteResearch use only, not for human use.
-
Brief DescriptionDMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
-
DescriptionDMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptormTOR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1685280-21-0
-
Formula Weight489.94
-
Molecular FormulaC15H8Br3NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=[N+](C(C(C1=CC=C(Br)C=C1)O2)=CC3=C2C(Br)=CC(Br)=C3)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.amélie, fouqué, Delalande O , Jean M , et al. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells[J]. Journal of Medicinal Chemistry, 2015:6559-73.
molnova catalog



related products
-
Autogramin-1
Autogramin-1 potently inhibits starvation-induced autophagy with IC50 of 0.17 μM.
-
Seco Rapamycin sodiu...
Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.
-
Cbz-B3A
Cbz-B3A is a potent inhibitor of mTORC1 signalling, inhibits phosphorylation of eIF4E-binding protein 1 (4EBP1) and blocks translation by 68%.